Gauthier, SergeFeldman, Howard HSchneider, Lon SWilcock, Gordon KFrisoni, Giovanni BHardlund, Jiri HMoebius, Hans JBentham, PeterKook, Karin AWischik, Damon JSchelter, Bjoern ODavis, Charles SStaff, Roger TBracoud, LucShamsi, KohkanStorey, John M DHarrington, Charles RWischik, Claude M2017-05-162017-05-162016-12Gauthier, S, Feldman, H H, Schneider, L S, Wilcock, G K, Frisoni, G B, Hardlund, J H, Moebius, H J, Bentham, P, Kook, K A, Wischik, D J, Schelter, B O, Davis, C S, Staff, R T, Bracoud, L, Shamsi, K, Storey, J M D, Harrington, C R & Wischik, C M 2016, 'Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease : a randomised, controlled, double-blind, parallel-arm, phase 3 trial ', The Lancet, vol. 388, no. 10062, pp. 2873-2884. https://doi.org/10.1016/S0140-6736(16)31275-20140-6736ORCID: /0000-0002-5261-5467/work/73579120ORCID: /0000-0003-2250-3920/work/47672890http://hdl.handle.net/2164/8639The study was financed by TauRx Therapeutics Ltd.12102121333110engR MedicineRJournal article10.1016/S0140-6736(16)31275-238810062